Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Bavarian Nordic National Institute of Allergy and Infectious Diseases (NIAID) |
---|---|
Information provided by: | Bavarian Nordic |
ClinicalTrials.gov Identifier: | NCT00189956 |
The objective of the study is to find the optimal dose for the smallpox candidate vaccine IMVAMUNE (MVA-BN). For this purpose the study compares IMVAMUNE (MVA-BN) administered at three different dose levels.
Condition | Intervention | Phase |
---|---|---|
Smallpox |
Biological: IMVAMUNE (MVA-BN) |
Phase II |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Dose Comparison, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Phase II, Double-Blind, Randomised, Dose-Finding Study to Evaluate the Immunogenicity of Three Different Doses of MVA-BN Smallpox Vaccine in 18-30 Year Old Smallpox naïve Healthy Subjects |
Ages Eligible for Study: | 18 Years to 30 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | POX-MVA-004, NIH N01-AI-30016 |
Study First Received: | September 11, 2005 |
Last Updated: | September 11, 2005 |
ClinicalTrials.gov Identifier: | NCT00189956 |
Health Authority: | United States: Food and Drug Administration; Switzerland: Swissmedic |
Virus Diseases Smallpox Signs and Symptoms |
Poxviridae Infections DNA Virus Infections Healthy |